Approved indications: Horizant is FDA-approved in adults for two conditions: (1) treatment of moderate-to-severe primary restless legs syndrome (RLS), and (2) management of postherpetic neuralgia (PHN), the chronic nerve pain that can persist after shingles.

Off-label uses: Off-label use of Horizant itself is relatively uncommon; for other neuropathic pain conditions (such as diabetic neuropathy), clinicians more often use immediate-release gabapentin or other agents, and evidence specifically supporting Horizant for these conditions is limited, so such use is individualized and based on specialist judgment.

Efficacy in restless legs syndrome: Many adults with RLS begin to notice improvement in leg discomfort and sleep within the first week of taking 600 mg once daily in the early evening, with further benefit over several weeks; in trials, this dose reduced RLS symptom scores and improved sleep compared with placebo, with similar overall effectiveness to other modern RLS options but often with less risk of dopamine-agonist–related problems like augmentation or impulse-control issues.

Efficacy in postherpetic neuralgia: For PHN, Horizant titrated to 600 mg twice daily has been shown to significantly reduce 24‑hour average pain scores and improve sleep and overall pain interference compared with placebo, with meaningful pain relief for many patients over about 1–2 weeks and continuing over 12–13 weeks of treatment.

Comparison with similar drugs: Because Horizant is an extended-release prodrug of gabapentin, it provides smoother, dose‑proportional gabapentin levels over 24 hours and comparable or better pain and symptom control than standard gabapentin at somewhat lower gabapentin-equivalent exposure, but overall effectiveness is in the same general range as other gabapentinoids and first‑line neuropathic pain treatments.

Typical adult dosing: For restless legs syndrome, the usual dose is 600 mg once daily taken at about 5 PM with food. For postherpetic neuralgia, treatment typically starts with 600 mg in the morning for 3 days, then increases to 600 mg twice daily (total 1,200 mg/day), with higher doses not providing additional benefit but increasing side effects.

How to take: Swallow Horizant extended‑release tablets whole with food; do not cut, crush, or chew them. Take doses at the same times each day, and do not substitute Horizant milligram‑for‑milligram with other gabapentin products because their absorption and dosing are different.

Special dosing instructions: People with reduced kidney function require lower or less frequent doses as directed by their clinician, and Horizant is not recommended for RLS in patients receiving hemodialysis. Dose changes or discontinuation should usually be done gradually to reduce the risk of withdrawal symptoms or seizures.

Missed dose guidance: For RLS, if a dose is missed, the patient should skip it and take the usual 600 mg dose at about 5 PM the next day; do not double up. For PHN, if a dose is missed, it should generally be skipped and the next scheduled dose taken at the usual time, without taking extra tablets to “catch up.”

Overdose: Taking too much Horizant can cause marked sleepiness, dizziness, double vision, slurred speech, or loss of coordination, and may worsen breathing if combined with other sedating drugs; in suspected overdose, emergency medical care and/or the Poison Help line (1‑800‑222‑1222 in the U.S.) should be contacted immediately.

Common side effects: The most frequent side effects are sleepiness/sedation, dizziness, and headache, and in some people fatigue, nausea, or swelling in the legs; these usually start in the first days of therapy or after a dose increase, are often mild to moderate, and tend to improve over several weeks as the body adjusts.

Serious or rare adverse effects: Seek immediate medical attention for signs of a severe allergic or hypersensitivity reaction (such as rash, hives, fever, swollen lymph nodes, facial or throat swelling, trouble breathing, or dark urine and yellowing of the skin or eyes), drug reaction with eosinophilia and systemic symptoms (DRESS), severe dizziness or confusion, new or worsening breathing problems (slow or shallow breathing, bluish lips or fingers), or signs of suicidal thoughts or behavior (new or worsening depression, agitation, or thoughts of self‑harm).

Warnings and precautions: Horizant can impair driving and the operation of machinery, especially at the start of treatment or after dose increases, so patients should not drive until they know how it affects them. Like other antiepileptic drugs, it can increase the risk of suicidal thoughts or behaviors, so mood and behavior changes should be monitored. Abruptly stopping the drug can increase the risk of seizures or withdrawal‑type symptoms; doses should usually be tapered under medical guidance. Dose reductions are required in kidney impairment, and RLS treatment is not recommended in patients on hemodialysis. Use in pregnancy and breastfeeding requires weighing potential benefits and risks with a clinician, as human data are limited and animal data suggest potential fetal harm.

Respiratory and CNS depression: Horizant can cause serious respiratory depression, particularly when combined with opioids, benzodiazepines, sleep medicines, or other central nervous system depressants, or in people with existing lung disease or in older adults; such patients should be monitored closely and may need lower starting doses.

Comparative safety: Compared with many other neuropathic pain medicines, Horizant has relatively few direct drug–drug interactions and is not metabolized by common liver enzymes, but sedation, dizziness, and fall risk—especially in older adults—are similar to other gabapentinoids and must be considered.

Reporting and safety updates: Side effects can be reported to the FDA MedWatch program (online or by calling 1‑800‑FDA‑1088), and up‑to‑date safety communications and prescribing information are available on the FDA and manufacturer websites.

CNS depressants and alcohol: Horizant’s sedating effects can add to those of opioids, benzodiazepines, sleep medicines, muscle relaxants, sedating antidepressants, antihistamines, and alcohol, increasing the risk of severe drowsiness, breathing problems, and falls; such combinations should be used only with caution, at the lowest effective doses, and under close medical supervision, and alcohol is best avoided while taking Horizant.

Other medicines and supplements: Horizant has few classic liver-enzyme–based drug interactions, but antacids containing aluminum or magnesium can reduce gabapentin absorption, so spacing these at least a couple of hours apart may be advised. Always inform your clinician about all prescription and over-the-counter medicines, vitamins, and herbal supplements (such as opioids, pregabalin, other gabapentin products, or sedating agents) before starting Horizant.

Medical conditions and precautions: Use requires particular caution and possible dose adjustment in people with kidney disease, chronic lung disease or sleep apnea, a history of depression or suicidal thoughts, seizure disorders, or significant heart or liver disease, and Horizant is not recommended for patients with RLS who must sleep during the day and remain awake at night.

Monitoring needs: Routine blood tests are not usually required solely for Horizant, but clinicians often monitor kidney function, mental health status, daytime alertness, balance and fall risk, and in high‑risk patients, signs of respiratory depression, adjusting the dose or regimen as needed.

Q: How long does it take for Horizant to start working for restless legs?
A: Many people notice some improvement in leg discomfort and sleep within about a week of starting 600 mg once daily, but it can take several weeks to reach full benefit.

Q: Can I take Horizant during the day instead of at 5 PM?
A: For restless legs syndrome, Horizant is designed to be taken once daily in the early evening (around 5 PM) so that the drug level matches nighttime symptoms, and any change in timing should be made only under your clinician’s guidance.

Q: Is Horizant the same as regular gabapentin?
A: No; Horizant is an extended-release prodrug of gabapentin with different absorption and dosing, so it cannot be directly substituted milligram-for-milligram with other gabapentin products.

Q: Can I drink alcohol while taking Horizant?
A: Alcohol can increase drowsiness and the risk of breathing problems with Horizant, especially if you also take other sedating medicines, so it is generally recommended to avoid or strictly limit alcohol and discuss any use with your clinician.

Q: What should I do if I want to stop taking Horizant?
A: Do not stop Horizant suddenly on your own; your prescriber will usually give you a schedule to taper the dose gradually to lower the risk of withdrawal symptoms or seizures and to watch for any return of pain or restless legs symptoms.

Storage: Store Horizant tablets at room temperature (about 68°F to 77°F / 20°C to 25°C), in a dry place away from excessive heat, moisture, and light, and keep the tablets in their original, tightly closed container and out of reach of children and pets.

Handling: Do not cut, crush, or chew the extended-release tablets; swallow them whole.

Disposal: When tablets are no longer needed or are expired, use a community drug take-back program if available; if none is available, mix the tablets (do not crush) with an undesirable substance (such as used coffee grounds or cat litter), seal in a disposable container or bag, and place in household trash, and remove or black out any personal information on empty prescription bottles before discarding.